How The PROCEPT BioRobotics (PRCT) Investment Story Is Shifting After Q4 Miss And Guidance Reset

AI Briefing

• – Investors reassess PRCT's long-term adoption potential for Aquablation technology
• – Analysts weigh near-term execution risks after Q4 miss and guidance reset
• – PRCT's model fair value remains steady at $30.44 per share